{"id":"elbasvir-grazoprevir","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Elevated transaminases"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Elbasvir inhibits the HCV NS5A protein, which is essential for viral RNA replication and virion assembly. Grazoprevir inhibits the HCV NS3/4A serine protease, which is required for processing of the HCV polyprotein. Together, these two direct-acting antivirals (DAAs) suppress HCV replication through complementary mechanisms.","oneSentence":"Elbasvir/Grazoprevir is a fixed-dose combination of a hepatitis C virus (HCV) NS5A inhibitor and NS3/4A protease inhibitor that blocks viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:03.639Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotypes 1, 4, 5, and 6"}]},"trialDetails":[{"nctId":"NCT02940496","phase":"PHASE2","title":"Pembrolizumab (MK-3475) in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-12-09","conditions":"BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection","enrollment":15},{"nctId":"NCT02890719","phase":"PHASE3","title":"Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.","status":"WITHDRAWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2016-08-03","conditions":"Liver Transplantation, Hepatitis C","enrollment":""},{"nctId":"NCT04048850","phase":"","title":"Zepatier in Patients with Substance Use","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2019-09-20","conditions":"Hepatitis C, Hiv, Coinfection, HIV","enrollment":25},{"nctId":"NCT02902120","phase":"PHASE4","title":"HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2017-05-01","conditions":"Hepatitis C, Renal Insufficiency, Chronic, Disorder of Transplanted Kidney","enrollment":21},{"nctId":"NCT02743897","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-05-01","conditions":"End Stage Renal Disease","enrollment":62},{"nctId":"NCT03379506","phase":"PHASE2","title":"Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-01-25","conditions":"HCV Infection","enrollment":57},{"nctId":"NCT03823911","phase":"PHASE4","title":"Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-11-18","conditions":"Cardiovascular Diseases, Hepatitis C, Hiv","enrollment":87},{"nctId":"NCT03797066","phase":"PHASE4","title":"ATTIC - Access To Treat in the Community","status":"TERMINATED","sponsor":"King's College Hospital NHS Trust","startDate":"2019-03-23","conditions":"Hepatitis C, Chronic","enrollment":13},{"nctId":"NCT03724149","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Lungs Into Negative Lung Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-12-12","conditions":"Lung Diseases","enrollment":10},{"nctId":"NCT02858050","phase":"","title":"Portal-724 MEMS for Medication Adherence Patients Taking HCV Medications","status":"COMPLETED","sponsor":"Saint Michael's Medical Center","startDate":"2016-09-09","conditions":"Adherence","enrollment":40},{"nctId":"NCT03496233","phase":"PHASE3","title":"Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo","startDate":"2018-09-19","conditions":"Chronic HCV Hepatitis","enrollment":75},{"nctId":"NCT03144440","phase":"","title":"Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel","status":"COMPLETED","sponsor":"Carmel Medical Center","startDate":"2016-12-13","conditions":"Hepatitis C","enrollment":200},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":"Chronic Hepatitis C Infection","enrollment":1128},{"nctId":"NCT03365635","phase":"PHASE4","title":"Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-09-22","conditions":"Hepatitis C, Hemodialysis, Nosocomial Infection","enrollment":6},{"nctId":"NCT02786537","phase":"PHASE4","title":"Study of Oral Treatments for Hepatitis C","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":1275},{"nctId":"NCT03146741","phase":"PHASE1, PHASE2","title":"Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-05-16","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT03236506","phase":"PHASE2","title":"A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2018-01-19","conditions":"Hepatitis C","enrollment":129},{"nctId":"NCT03127358","phase":"NA","title":"Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2017-11-14","conditions":"Hepatitis C, Medication Adherence","enrollment":11},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":"Hepatitis C, Chronic","enrollment":300},{"nctId":"NCT03723824","phase":"PHASE4","title":"Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation","status":"TERMINATED","sponsor":"Taichung Veterans General Hospital","startDate":"2019-02-14","conditions":"Chronic Hepatitis c, Liver Transplant Infection, Kidney Transplant Infection","enrollment":14},{"nctId":"NCT02133131","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-13","conditions":"Hepatitis C","enrollment":143},{"nctId":"NCT02105701","phase":"PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-05","conditions":"Hepatitis C Infection","enrollment":420},{"nctId":"NCT02105662","phase":"PHASE3","title":"An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-03","conditions":"Chronic Hepatitis C","enrollment":218},{"nctId":"NCT01717326","phase":"PHASE2","title":"A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-07","conditions":"Hepatitis C","enrollment":573},{"nctId":"NCT01932762","phase":"PHASE2","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-01","conditions":"Hepatitis C","enrollment":98},{"nctId":"NCT03578640","phase":"PHASE3","title":"Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4","status":"COMPLETED","sponsor":"King Fahad Medical City","startDate":"2018-07-01","conditions":"Hepatitis C, Chronic","enrollment":30},{"nctId":"NCT03093415","phase":"PHASE4","title":"Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2017-05-30","conditions":"Hepatitis C, Substance Use Disorders, Substance Abuse, Intravenous","enrollment":100},{"nctId":"NCT03817619","phase":"PHASE1","title":"Bioequivalence Study of Crushed Elbasvir/Grazoprevir Compared to the Whole Tablet","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2019-03-28","conditions":"Hepatitis C, Deglutition Disorders","enrollment":11},{"nctId":"NCT02973503","phase":"PHASE3","title":"Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2017-01-11","conditions":"Chronic HCV Infection","enrollment":117},{"nctId":"NCT04546802","phase":"PHASE3","title":"HepATocellular Cancer Hcv Therapy Study","status":"WITHDRAWN","sponsor":"Bayside Health","startDate":"2019-09","conditions":"Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma","enrollment":""},{"nctId":"NCT03111108","phase":"PHASE4","title":"Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-06-20","conditions":"Hepatitis C Virus (HCV) Infection","enrollment":117},{"nctId":"NCT02945150","phase":"PHASE4","title":"Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-02-01","conditions":"Renal Failure","enrollment":8},{"nctId":"NCT03381859","phase":"PHASE4","title":"Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2019-12-01","conditions":"Hepatitis C Virus Infection, Response to Therapy of","enrollment":""},{"nctId":"NCT03249194","phase":"EARLY_PHASE1","title":"Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2017-08-17","conditions":"Kidney Transplant, Hepatitis C","enrollment":25},{"nctId":"NCT03420300","phase":"PHASE4","title":"EBR/GZR for HCV-1b Patients Receiving Hemodialysis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2018-06-05","conditions":"Hepatitis C","enrollment":40},{"nctId":"NCT02940691","phase":"PHASE4","title":"Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs","status":"TERMINATED","sponsor":"Kirby Institute","startDate":"2017-05-01","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT03791814","phase":"PHASE4","title":"A Prospective Cohort Study to Improve HCV Care in Dialysis Patients","status":"WITHDRAWN","sponsor":"Albert Einstein Healthcare Network","startDate":"2019-01-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT03037151","phase":"PHASE4","title":"Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV","status":"UNKNOWN","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2018-08-01","conditions":"Compensated Cirrhosis","enrollment":100},{"nctId":"NCT02886624","phase":"PHASE2","title":"Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4","status":"COMPLETED","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2017-05-31","conditions":"Acute Hepatitis C, HIV","enrollment":30},{"nctId":"NCT02895958","phase":"PHASE4","title":"The Dublin Zepatier Study","status":"TERMINATED","sponsor":"Mater Misericordiae University Hospital","startDate":"2018-03-15","conditions":"Hepatitis C","enrollment":3},{"nctId":"NCT02105688","phase":"PHASE3","title":"An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-02","conditions":"Chronic Hepatitis C","enrollment":301},{"nctId":"NCT04063839","phase":"","title":"HCV Treatment in a Low-threshold Clinic","status":"UNKNOWN","sponsor":"University Hospital, Akershus","startDate":"2015-01","conditions":"Hepatitis C, Substance Use Disorders","enrollment":300},{"nctId":"NCT03221582","phase":"PHASE4","title":"Impact of Hepatitis C Therapy and Bone Health","status":"TERMINATED","sponsor":"Dallas VA Medical Center","startDate":"2017-08-28","conditions":"Human Immunodeficiency Virus, Hepatitis C","enrollment":6},{"nctId":"NCT02601573","phase":"PHASE2","title":"Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-05","conditions":"Hepatitis C","enrollment":101},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT02332720","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-01-28","conditions":"Hepatitis C","enrollment":413},{"nctId":"NCT02332707","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-01-22","conditions":"Hepatitis C","enrollment":443},{"nctId":"NCT02600325","phase":"PHASE3","title":"Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2016-02","conditions":"Acute Hepatitis C, Human Immunodeficiency Virus, Hepatitis C","enrollment":80},{"nctId":"NCT02115321","phase":"PHASE2, PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-09","conditions":"Chronic Hepatitis C","enrollment":40},{"nctId":"NCT01937975","phase":"PHASE1","title":"The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-09-06","conditions":"Chronic Hepatitis C, Renal Impairment","enrollment":24},{"nctId":"NCT03144635","phase":"PHASE4","title":"A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2017-04-01","conditions":"Hepatitis C Viral, Chronic Kidney Disease stage3","enrollment":80},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT03706222","phase":"","title":"Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2018-10-22","conditions":"Drug Interaction Potentiation","enrollment":400},{"nctId":"NCT02897596","phase":"PHASE3","title":"Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2017-04-28","conditions":"Hepatitis C, HIV","enrollment":62},{"nctId":"NCT03111966","phase":"","title":"Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort","status":"COMPLETED","sponsor":"Hepa C","startDate":"2017-03-31","conditions":"Hepatitis C","enrollment":130},{"nctId":"NCT02251990","phase":"PHASE3","title":"Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-01-28","conditions":"Hepatitis C","enrollment":489},{"nctId":"NCT03186365","phase":"PHASE3","title":"8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2017-06-12","conditions":"Hepatitis C, Chronic","enrollment":82},{"nctId":"NCT03026023","phase":"PHASE4","title":"Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant","status":"WITHDRAWN","sponsor":"Raymond T. Chung, MD","startDate":"2018-08-01","conditions":"Cardiac Transplant Disorder, Hepatitis C","enrollment":""},{"nctId":"NCT03093740","phase":"PHASE4","title":"Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2018-10-01","conditions":"Renal Failure Chronic, Hepatitis C","enrollment":""},{"nctId":"NCT03098121","phase":"PHASE4","title":"Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection","status":"COMPLETED","sponsor":"Taoyuan General Hospital","startDate":"2017-10-20","conditions":"Chronic Hepatitis C","enrollment":40},{"nctId":"NCT02358044","phase":"PHASE3","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT02252016","phase":"PHASE3","title":"Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-10-22","conditions":"Hepatitis C","enrollment":159},{"nctId":"NCT02105467","phase":"PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-05","conditions":"Chronic Hepatitis C Virus","enrollment":421},{"nctId":"NCT02105454","phase":"PHASE2","title":"Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"Hepatitis C Virus","enrollment":79},{"nctId":"NCT02092350","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-17","conditions":"Hepatitis C Virus","enrollment":237},{"nctId":"NCT02203149","phase":"PHASE2, PHASE3","title":"Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-01","conditions":"Hepatitis C","enrollment":399},{"nctId":"NCT02781649","phase":"PHASE4","title":"Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2016-07-20","conditions":"End-Stage Renal Disease, Hepatitis C","enrollment":10},{"nctId":"NCT02785666","phase":"PHASE3","title":"Swiss HCVree Trial","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2016-06","conditions":"Hepatitis C, HIV","enrollment":150},{"nctId":"NCT03585101","phase":"PHASE4","title":"A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2018-08","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT03105349","phase":"PHASE4","title":"A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A","status":"WITHDRAWN","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2017-07-01","conditions":"HCV","enrollment":""},{"nctId":"NCT03407703","phase":"","title":"Hepatitis C (HCV) Cure and Kidney Health","status":"UNKNOWN","sponsor":"San Francisco Veterans Affairs Medical Center","startDate":"2018-03-27","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03145623","phase":"","title":"Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-06-02","conditions":"Hepatitis C, Chronic Kidney Diseases","enrollment":100},{"nctId":"NCT03433326","phase":"","title":"Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy","status":"UNKNOWN","sponsor":"University of Florence","startDate":"2018-03-01","conditions":"Hepatitis C, Cryoglobulinaemic Glomerulonephritis","enrollment":45},{"nctId":"NCT03359746","phase":"PHASE4","title":"Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2017-12-15","conditions":"Hepatitis C","enrollment":40},{"nctId":"NCT03143998","phase":"PHASE4","title":"Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-02-12","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT03222167","phase":"PHASE3","title":"Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b","status":"UNKNOWN","sponsor":"Institute Of Cardiology & Internal Diseases, Kazakhstan","startDate":"2017-10","conditions":"Chronic Hepatitis C Genotype 1B, Metabolic Syndrome, Fibrosis, Liver","enrollment":60},{"nctId":"NCT02647632","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01","conditions":"Hepatitis C","enrollment":26},{"nctId":"NCT03110055","phase":"NA","title":"the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC.","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2017-05-01","conditions":"HCV, HCC","enrollment":20},{"nctId":"NCT03022006","phase":"PHASE4","title":"Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Norte Study Group","startDate":"2017-01-15","conditions":"Chronic Hepatitis C","enrollment":60},{"nctId":"NCT02057003","phase":"","title":"Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients","status":"UNKNOWN","sponsor":"Valme University Hospital","startDate":"2012-01","conditions":"Hepatitis C, Chronic, Human Immunodeficiency Virus","enrollment":1000},{"nctId":"NCT02732405","phase":"PHASE3","title":"Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis","status":"UNKNOWN","sponsor":"Istituto Clinico Humanitas","startDate":"2016-05","conditions":"Hepatitis C, Compensated Cirrhosis","enrollment":120},{"nctId":"NCT02204475","phase":"PHASE3","title":"Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11","conditions":"Hepatitis C","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":18,"reaction":"TREATMENT FAILURE"},{"count":16,"reaction":"HEPATITIS C"},{"count":14,"reaction":"OSTEOPOROSIS"},{"count":12,"reaction":"FOOT FRACTURE"},{"count":11,"reaction":"DRUG RESISTANCE"},{"count":11,"reaction":"NAUSEA"},{"count":10,"reaction":"FIBROSIS"},{"count":10,"reaction":"HEADACHE"},{"count":9,"reaction":"INSOMNIA"},{"count":9,"reaction":"PRURITUS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-8742/MK-5172","Zepatier (BR); Elbasvir-Grazoprevir (SY); Grazoprevir/Elbasvir (SY); Grazoprevir-Elbasvir (SY); MK-8742/ MK-5172 (CN)","Zepatier","Zepatier, serial number 86336186"],"phase":"marketed","status":"active","brandName":"Elbasvir/Grazoprevir","genericName":"Elbasvir/Grazoprevir","companyName":"University of Florence","companyId":"university-of-florence","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Elbasvir/Grazoprevir, a small molecule, is a fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg, available as oral tablets. It is indicated for the treatment of Chronic Hepatitis C, among other conditions, as per ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-01-28T00:00:00.000Z","mah":"MSD SUB MERCK","brand_name_local":"ZEPATIER","application_number":"NDA208261"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}